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Introduction {#path5171-sec-0001}
============

Wilms tumour is the most common renal neoplasm in children. Its biology and morphology closely mirror the early stages of mammalian kidney development (nephrogenesis). A key element of nephrogenesis is the transformation of the blastemal elements of the metanephric mesenchyme, via mesenchymal‐to‐epithelial transition (MET), into the functional units of the kidney, the nephrons. MET is initiated by reciprocal induction between the ureteric bud (UB) and the blastema, followed by polarisation and differentiation of the blastema via gradually maturing epithelial structures, such as renal vesicles, comma‐shaped bodies (CSB) and S‐shaped bodies (SSB), that ultimately form tubules and glomeruli [1](#path5171-bib-0001){ref-type="ref"}. Wilms tumours result from a disturbance of these processes with the accumulation of cells that retain features of the immature metanephric mesenchyme/blastema, with a variable degree of differentiation towards epithelial and stromal elements. This explains the tumour\'s classic triphasic histology. Tumours with a predominance of blastemal cells after treatment are associated with inferior prognosis, as are tumours with regions harbouring pleomorphic and disorganised cells, a feature referred to as diffuse anaplasia [2](#path5171-bib-0002){ref-type="ref"}. Wilms tumour patients currently have an overall survival rate approaching 90%, but this comes at the price of heavy chemotherapy, often resulting in severe and/or life‐long side effects [3](#path5171-bib-0003){ref-type="ref"}, [4](#path5171-bib-0004){ref-type="ref"}. Identification of agents that could induce differentiation of Wilms tumour cells into nephrogenic structures could be a future route towards reducing cytotoxic treatment.

Somatic mutations and chromosomal rearrangements have been associated with high‐risk histological features and inferior outcome in Wilms tumour patients. Among those are hemizygous deletions in chromosome arm 16q [5](#path5171-bib-0005){ref-type="ref"}. The smallest region of genomic overlap between these deletions has been shown to harbour the Iroquois homebox B (IRXB) gene cluster, consisting of *IRX3*, *IRX5* and *IRX6* [6](#path5171-bib-0006){ref-type="ref"}. *IRX3* and *IRX5* encode proteins that have recently been shown to be essential for several aspects of embryogenesis, such as the development of the nervous system, heart and skeleton [7](#path5171-bib-0007){ref-type="ref"}, [8](#path5171-bib-0008){ref-type="ref"}, [9](#path5171-bib-0009){ref-type="ref"}, [10](#path5171-bib-0010){ref-type="ref"}, [11](#path5171-bib-0011){ref-type="ref"}. The Iroquois genes *Irx3* and *Irx5* are both expressed in the developing mouse kidney [12](#path5171-bib-0012){ref-type="ref"}, but so far, no specific function for Irx5 in nephrogenesis has been reported [13](#path5171-bib-0013){ref-type="ref"}. Irx3, on the other hand, has been shown to be important in nephron formation and segmentation in both Xenopus and zebrafish [14](#path5171-bib-0014){ref-type="ref"}, [15](#path5171-bib-0015){ref-type="ref"}, [16](#path5171-bib-0016){ref-type="ref"}. This background encouraged us to further study the roles of IRX3 and IRX5 in Wilms tumour and kidney development with the ultimate purpose of identifying signalling pathways that could be manipulated for the induction of Wilms tumour differentiation.

Materials and methods {#path5171-sec-0002}
=====================

Mouse models, patient material and human cell lines {#path5171-sec-0003}
---------------------------------------------------

One wild type (*wt*), four *Irx3/Irx5* ^+/−^ and four *Irx3/Irx5* ^−/−^ E13.5 foetal mouse kidneys were available for analysis [11](#path5171-bib-0011){ref-type="ref"}. Mouse experiments were performed following ethics permit 'Mouse Limb Development' \#33868 (Mouse) approval by the Hospital for Sick Children Animal Care Committee, Toronto, Canada. Use of patient material was approved by the Regional Ethics Review Board with approval reference numbers L605‐2005 (biobanking), L289‐2011 (molecular analyses of tumours) and L796‐2017 (analysis of anonymised post‐mortem material), according to the Helsinki Declaration of 1975, as revised in 1983. Material from 39 primary Wilms tumours, two anonymised postnatal kidneys and five anonymised foetal kidneys were analysed (see supplementary material, Table [S1](#path5171-supitem-0011){ref-type="supplementary-material"}). The Wilms tumour WiT49 cell line, kindly provided by Dr. Yeger at the Laboratory of Medicine and Pathobiology, University of Toronto, Canada [17](#path5171-bib-0017){ref-type="ref"}, has been repeatedly characterised by our lab [18](#path5171-bib-0018){ref-type="ref"}, [19](#path5171-bib-0019){ref-type="ref"}. WiT49 cells were used to create *IRX3* and *IRX5* knockout cells through targeted genome editing to create *IRX3* ^−/−^ and *IRX5* ^−/−^ cells as detailed in the supplementary material, Supplementary materials and methods and Table [S2](#path5171-supitem-0012){ref-type="supplementary-material"}. *In vitro*, cells were cultured in DMEM F:12 1:1 supplemented with 10% foetal bovine serum and 1% penicillin--streptomycin.

Orthotopic xenograft transplantation and magnetic resonance imaging {#path5171-sec-0004}
-------------------------------------------------------------------

One million WiT49 wild‐type, *IRX3* ^−/−^ or *IRX5* ^−/−^ cells in 20 μl PBS were injected into the left kidney of female NSG mice (4--6 weeks old; Charles River Laboratories, Wilmington, MA, USA) as described previously [19](#path5171-bib-0019){ref-type="ref"}. Thirteen mice were injected with WiT49 wild‐type cells, 14 with *IRX3* ^−/−^ cells and 9 with *IRX5* ^−/−^ cells (see supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}). Magnetic resonance imaging (MRI) was performed 12 weeks after tumour cell injection as described previously (9.4 T horizontal bore, Lund University Bioimaging Center, Sweden; [20](#path5171-bib-0020){ref-type="ref"}). MRIs were scrutinised using the Sante DICOM viewer 3D (Santesoft, Nicosia, Cyprus). Tumour volumes were calculated using the DICOM viewer software OsiriX (Pixmeo SARL, Switzerland). Volume was registered as 0 if no tumour was visible or if rendered immeasurable by being present in one MRI section only (see supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}). Mice were sacrificed 3 months after xenotransplantation. Xenograft animal studies were performed according to ethics permit M11‐15 (Malmö‐Lund Animal Research Ethics Committee, Lund, Sweden).

Immunohistochemistry and histological imaging {#path5171-sec-0005}
---------------------------------------------

Paraffin‐embedded tissue was deparaffinised and prepared for immunohistochemistry (IHC) according to standard procedures. Details about antibodies, their working solutions and procedures can be found in supplementary material, Table [S4](#path5171-supitem-0014){ref-type="supplementary-material"} and Supplementary materials and methods. Slides subjected to IHC or haematoxylin and eosin (H&E) staining were scanned using an Aperio ImageScope v12.1.0.5029 (Leica Biosystems, Wetzlar, Germany) or photographed with a digital SC50 camera (Olympus, Tokyo, Japan).

For murine embryonic kidneys, UB‐derived CALB1‐positive structures were distinguished from N‐cadherin‐positive CSB and SSB, while E‐cadherin was used to identify all epithelial foetal kidney components. CALB1‐immunostained sections were compared to consecutive sections stained for E‐cadherin to confirm the classification of CSB and SSB as opposed to UB‐derived structures. The total number (*n*) of CALB1‐ and N‐cadherin‐stained sections available for analysis in each group was: wild type: *n* = 3; *Irx3/Irx5* ^+/−^: *n* = 14; and *Irx3/Irx5* ^−/−^: *n* = 8. The Wilcoxon rank‐sum test was used for significance tests. For analysis of clinical Wilms tumour samples, a tissue microarray (TMA) with cores from 33 primary tumours was used for the evaluation of IRX3 and IRX5 protein expression [21](#path5171-bib-0021){ref-type="ref"}. IRX3 and IRX5 were categorised as present or absent (see supplementary material, Table [S1](#path5171-supitem-0011){ref-type="supplementary-material"}).

Xenograft Wilms tumours were evaluated for the percentage of tumour surface area consisting of neoplastic tubules. Positive WT1 expression identified tubular epithelial cells, whereas p53 positivity was used for demarcation of tumour borders in contrast to host mouse kidney tissue (see supplementary material, Figure [S1](#path5171-supitem-0003){ref-type="supplementary-material"}). Thirteen wild‐type WiT49 tumours, 12 *IRX3* ^−/−^ tumours \[C2 (*n* = 6) and T5_40 (*n* = 6)\] and 7 *IRX5* ^−/−^ tumours \[T5_34 (*n* = 2), T5_71 (*n* = 3) and T5_77 (*n* = 2)\] provided sufficient tumour material for analysis (see supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}). Evaluation of WNT5A expression was performed on sections from four WiT49 wild‐type, six *IRX3* ^−/−^ and two *IRX5* ^−/−^ xenograft tumours (see supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}). All tumour areas containing stroma were digitalised, and all stroma cells \[wild type (*n* = 3054 cells), *IRX3* ^−/−^ (*n* = 5010 cells) and *IRX5* ^−/−^ (*n* = 1115 cells)\] were scored as positive or negative for WTN5A protein expression. Fisher\'s exact test (two‐sided) was used to evaluate any differences between groups.

RNA and protein extraction and gene and protein expression analyses {#path5171-sec-0006}
-------------------------------------------------------------------

WiT49 wild‐type (*n* = 5), *IRX3* knockout \[C2 (*n* = 3) and T5_40 (*n* = 3)\] and *IRX5* knockout (one each of T5_34, T5_71, T5_77, T5_56 and T5_110) cells were seeded and grown for 48 h. Biological replicates were grown for WiT49, C2 and T5_40 in order to increase the number of samples for statistical analysis. For global gene expression analyses, whole transcriptome RNA sequencing was performed on an Ion Ampliseq (Thermo Fisher Scientific, Waltham, MA, USA) at the National Genomics Infrastructure, SciLife Uppsala Core Facility, Uppsala, Sweden. To explore active signalling pathways in *IRX3* ^*−/−*^ and *IRX5* ^*−/−*^ cells, gene expression data were analysed by Gene Set Enrichment Analysis (GSEA; [22](#path5171-bib-0022){ref-type="ref"}, [23](#path5171-bib-0023){ref-type="ref"}; GSEA 3.0 (<http://www.broadinstitute.org/gsea/>), Broad Institute, Cambridge, MA, USA). For targeted pathway analysis, Qlucore Omics Explorer 3.2 and 3.3 (Qlucore, Lund, Sweden) were used. Further details for gene expression analysis and information about protein extraction and Western blotting are provided in supplementary material, Supplementary materials and methods.

Cell proliferation assays {#path5171-sec-0007}
-------------------------

Cell proliferation assays were performed on the original WiT49 clone and its *IRX3* ^−/−^ and *IRX5* ^−/−^ clones using an MTS assay (CellTiter 96^®^ AQueous One Solution Cell Proliferation Assay, G3582, Promega, Madison, WI, USA) and IncuCyteZoom^®^ (Essen BioScience, Ann Arbor, MI, USA). For details, see supplementary material, Supplementary materials and methods.

Results {#path5171-sec-0008}
=======

Reduced nephron morphogenesis in *Irx3*/*Irx5* knockout mice {#path5171-sec-0009}
------------------------------------------------------------

To evaluate whether Irx3 and Irx5 influence normal mammalian kidney development, we first turned to an already established mouse model in which *Irx3* and *Irx5* had been either heterozygously or homozygously deleted [11](#path5171-bib-0011){ref-type="ref"}. Given that Irx3 and Irx5 show redundant functions in mouse heart development, we chose to study double‐knockout embryos when probing for an effect on nephrogenesis [8](#path5171-bib-0008){ref-type="ref"}, [24](#path5171-bib-0024){ref-type="ref"}. *Irx3/Irx5* ^−/−^ embryos die at E13.5 due to heart failure [8](#path5171-bib-0008){ref-type="ref"}, [11](#path5171-bib-0011){ref-type="ref"}. Therefore, we examined nephron formation during early kidney development (E13.5) and compared mice of *wt* or in which *Irx3* and *Irx5* had been either heterozygously or homozygously deleted (Figure [1](#path5171-fig-0001){ref-type="fig"}). N‐cadherin immunostaining was used to identify cells and structures destined to become parts of proximal tubules, including SSB and CSB. Compared to *wt* and *Irx3/5* ^+/−^ mice, maturing nephrogenic epithelial elements were close to absent in *Irx3/Irx5* ^−/−^ mice (Figure [1](#path5171-fig-0001){ref-type="fig"}M--R). CSB and SSB were significantly more prevalent in *wt* compared to *Irx3*/*Irx5* ^+/−^ (*p* = 0.022) and *Irx3*/*Irx5* ^−/−^ (*p* = 0.013) embryonal mouse kidneys (Wilcoxon rank‐sum test, Figure [1](#path5171-fig-0001){ref-type="fig"}S). This role for Irx3/Irx5 in murine nephron formation encouraged further delineation of IRX3 and IRX5 in a context of human nephrogenesis and Wilms tumour.

![Reduced nephron morphogenesis in *Irx3/Irx5* knockout mice. Representative images of *Irx3* and *Irx5 wt*, heterozygous and homozygous knockout E13.5 foetal mouse kidney (FMK) sections stained with H&E (Htx; A--C). The CM/committed blastema, identified by Six2 expression was retained in all genotypes (D--F), although it was more extensively manifested in homozygous (*Irx3* ^−/−^ *Irx5* ^−/−^) mice (F). *Irx3/5* ^−/−^ mice, as opposed to *wt* and heterozygous mice, showed N‐cadherin positivity largely confined to cells of the CM as if differentiation through CSB and SSB had ceased (G--L). Specific labelling of UB structures with CALB1 (M--O), in combination with staining for all epithelial elements in the foetal kidney by E‐cadherin (P--R), confirmed that almost all epithelial structures were UB‐derived in *Irx3/5* ^−/−^ mice (O and R). *Irx3*/*Irx5* knockout mice maintained the ability to form some primitive nephrogenic tubules with a distinct lumen and could dock to UB‐derived structures, but the tails of the SSB were consistently missing in *Irx3*/*Irx5* hetero‐ and homozygous knockout embryos, resulting in short tubules without curvature (K and L). Solid black lines demarcate the developing kidney from surrounding tissue (A--C). Arrows point to CSB and SSB in G and H. Content in rectangles with dashed lines in G--I are enlarged in J--L. Arrowheads point at docking sites between nephrogenic and UB‐derived epithelial structures, and asterisks (\*) denote the lumen of nephrogenic tubules in K--L. Dotted lines in M and N correspond to E‐cadherin‐positive structures in P and Q. Scale bars correspond to 200 μm. All immunostains are brown. Box plot showing the median number and quartiles of CSB and SSB in FMK (S), where n denote the number of sections analysed for CSB and SCB in each group.](PATH-247-86-g001){#path5171-fig-0001}

IRX3 and IRX5 are expressed in distinct tissue elements of foetal kidney and Wilms tumour {#path5171-sec-0010}
-----------------------------------------------------------------------------------------

In human foetal kidney specimens (Figure [2](#path5171-fig-0002){ref-type="fig"}), the nephrogenic epithelium was IRX3‐positive by IHC, whereas UB‐derived structures were negative (Figure [2](#path5171-fig-0002){ref-type="fig"}A--C). Primitive nephrogenic structures of the nephrogenic zone, such as renal vesicles, CSB and SSB, as well as mature proximal tubules were IRX3‐positive (Figure [2](#path5171-fig-0002){ref-type="fig"}D--F). The expression of IRX3 in cap mesenchyme (CM) was minimal (Figure [2](#path5171-fig-0002){ref-type="fig"}D,E), and its expression increased with the time of gestation (Figure [2](#path5171-fig-0002){ref-type="fig"}B,J,E), subsequently decreasing in the postnatal kidney (Figure [2](#path5171-fig-0002){ref-type="fig"}F,L; see supplementary material, Figure [S2](#path5171-supitem-0004){ref-type="supplementary-material"}A--D). IRX5 showed a similar expression pattern to IRX3 but was more prominently expressed in CM, renal vesicles and early‐stage nephrogenic tubules (Figure [2](#path5171-fig-0002){ref-type="fig"}G,H and supplementary material, Figure [S2](#path5171-supitem-0004){ref-type="supplementary-material"}E). IRX5 expression was retained in nephrons of postnatal normal kidney (Figure [2](#path5171-fig-0002){ref-type="fig"}I). IRX3 and IRX5 showed predominantly cytoplasmic expression, with little nuclear expression at early nephrogenesis and none in postnatal kidney (Figure [2](#path5171-fig-0002){ref-type="fig"}J--M). Similar to that observed in the human foetal kidney, IHC analysis of a TMA containing cores from ≥30 primary Wilms tumours demonstrated that IRX3 was expressed in the epithelial elements of almost all tumours, compared to blastemal components in a minority of cases, and in stromal components only very rarely (Figure [2](#path5171-fig-0002){ref-type="fig"}N--P, T and supplementary material, Figure [S2](#path5171-supitem-0004){ref-type="supplementary-material"}F). IRX5 was also expressed in epithelial components, but contrary to IRX3, it was also commonly expressed in blastemal and stromal elements (Figure [2](#path5171-fig-0002){ref-type="fig"}Q--T). The IRX3 and IRX5 proteins were detected in both nucleus and cytoplasm (Figure [2](#path5171-fig-0002){ref-type="fig"}N--S). Taken together, these results indicated that IRX3 may play a role primarily during maturation of nephrogenic elements, while IRX5 activity is also present in the stromal and proliferative late blastemal/early epithelial cells in developing kidneys and Wilms tumours.

![IRX3 and IRX5 are expressed in nephrogenic elements of human foetal kidney and distinct compartments of Wilms tumours. Expression of IRX3 and IRX5 proteins in human foetal and postnatal kidneys were identified by IHC. Consecutive sections of human kidney, at gestational week (gw) 16, were immunostained for CALB1 (A), IRX3 (B) and E‐cadherin (C). E‐cadherin was used for the detection of all epithelial structures of the kidney, and UB‐derived structures were characterised by CALB1 expression. Arrows with open heads point at CALB1‐positive/UB‐derived epithelial elements negative for IRX3. Open arrowheads point at IRX3 and E‐cadherin‐positive nephrogenic structures, which are negative for CALB1. IRX3‐ (D, E) and IRX5 (G, H)‐positive elements in human foetal (D, E and G, H) and postnatal kidney (PNK; F, I). Magnification of previous figures to illustrate cytoplasmic staining of IRX3 and IRX5, where scale bars correspond to 100 μm (J--M). Dotted lines indicate a border between the immature subcapsular nephrogenic zone (n.z.) and the more mature central zone (m.z.) of the developing kidney. Yellow asterisks denote cap/metanephric mesenchyme. Arrows point at the ruffled lumen of proximal tubules. Open arrowheads point at IRX3‐positive CSB and SSB. Filled arrowheads in G--H denote IRX5‐positive CSB and SSB. IRX3‐ (E, F) and IRX5 (H)‐negative glomeruli are denoted by hash (\#). Scale bars correspond to 200 μm. N--S: IRX3 and IRX5 protein expression evaluated by IHC in Wilms tumour (WT) histological sub‐compartments from which representative areas are shown (N--P and Q--S, respectively). Scale bars correspond to 100 μm. All immunostains are brown. (T) Bar chart summarising the frequency of IRX3‐ and IRX5‐positive blastemal (B), epithelial (E) and stromal (S) elements in primary Wilms tumours based on examination of a WT TMA (IRX3, *n* = 33 primary WTs; IRX5, *n* = 30 primary WTs; Table [S1](#path5171-supitem-0011){ref-type="supplementary-material"}).](PATH-247-86-g002){#path5171-fig-0002}

IRX3 and IRX5 knockout Wilms tumour cells have contrasting phenotypes *in vitro* {#path5171-sec-0011}
--------------------------------------------------------------------------------

To elucidate the functionality of IRX3 and IRX5 in Wilms tumour development, targeted genome editing of *IRX3* and *IRX5* was performed on the human WiT49 Wilms tumour cell line, chosen as a model system as it retains the multi‐phasic histology of Wilms tumours when orthotopically xenografted into mice [17](#path5171-bib-0017){ref-type="ref"}, [19](#path5171-bib-0019){ref-type="ref"}, [25](#path5171-bib-0025){ref-type="ref"}, [26](#path5171-bib-0026){ref-type="ref"}. Most importantly, the model enables the evaluation of tumour tubule formation, corresponding to Wilms tumour epithelial differentiation. Two *IRX3* and five *IRX5* knockout clones were successfully created (see supplementary material, Figure [S3](#path5171-supitem-0005){ref-type="supplementary-material"}, Table [S2](#path5171-supitem-0012){ref-type="supplementary-material"}). Attempts were made for the generation of *IRX3*/*IRX5* double‐knockout clones, but these were unsuccessful. *In vitro*, there were clear morphological differences between the knockout cell lines (see supplementary material, Figure [S4](#path5171-supitem-0006){ref-type="supplementary-material"}A--F), with *IRX5* ^−/−^ cells growing in epithelial monolayers, while *IRX3* ^−/−^ and *wt* cells had a fibroblast‐like appearance and formed tumour spherules. *IRX5* ^−/−^ knockout clones showed decreased proliferation by two independent methods compared to WiT49 and *IRX3* ^−/−^ cells (see supplementary material, Figure [S5](#path5171-supitem-0007){ref-type="supplementary-material"}). RNA sequencing of cultured cells (see supplementary material, Table [S5](#path5171-supitem-0015){ref-type="supplementary-material"}), followed by GSEA, demonstrated signatures of cell cycle regulators and progenitor cell renewal in *IRX3* ^−/−^ cells (see supplementary material, Table S6A and Figure S4G). In contrast, the expression of genes involved in nephrogenic maturation, such as cell polarity, epithelial sheet formation and development, was significantly enriched for in *IRX5* ^−/−^ cells (see supplementary material, Figure [S4](#path5171-supitem-0006){ref-type="supplementary-material"}H--J and Table S6B,C).

Lack of IRX3 blocks tubular maturation and promotes tumourigenesis *in vivo* {#path5171-sec-0012}
----------------------------------------------------------------------------

To simulate Wilms tumourigenesis *in vivo*, we performed orthotopic xenograft transplantation of 1 × 10^6^ *wt*, *IRX3* ^−/−^ or *IRX5* ^−/−^ WiT49 cells into the left kidney of immunodeficient NSG (NOD scid gamma) mice. MRI 12 weeks after transplantation repeatedly showed bulky tumour development from *wt* and *IRX3* ^−/−^ xenograft cells, with no difference in tumour size between the genotypes (Figures [3](#path5171-fig-0003){ref-type="fig"}A,B and [4](#path5171-fig-0004){ref-type="fig"}A; *p* = 0.56, Wilcoxon rank‐sum test). The tumours were readily visible macroscopically when the mice were sacrificed at 14--15 weeks after transplantation (Figure [3](#path5171-fig-0003){ref-type="fig"}D,E,G,H). Histologically, both *wt* and *IRX3* ^−/−^ xenograft tumours were dominated by a large mesenchymal/stromal compartment (Figures [3](#path5171-fig-0003){ref-type="fig"}J,K and [4](#path5171-fig-0004){ref-type="fig"}C--H), readily discernible from the murine host kidney cells through the endogenous accumulation of mutated p53 in WiT49 cells [17](#path5171-bib-0017){ref-type="ref"}. *Wt* and *IRX3* ^−/−^ tumours grew mostly in a sarcomatous fashion, displacing or engulfing nephrons and collecting ducts of the host kidney (Figures [3](#path5171-fig-0003){ref-type="fig"}M,N and [4](#path5171-fig-0004){ref-type="fig"}D,G). The areas of tumour tubules in *IRX3* ^−/−^ tumours were significantly reduced compared to those in *wt* tumours in accordance with a role for IRX3 in tubular maturation (Figure [4](#path5171-fig-0004){ref-type="fig"}B,E,H; *p* = 0.0002, Wilcoxon rank‐sum test).

![Distinct roles of IRX3 and IRX5 in orthotopic Wilms tumour xenografts. NSG mice were monitored by MRI 12 weeks after xenotransplantation of *wt* (A), *IRX3* ^*−/−*^ (B) or *IRX5* ^*−/−*^ (C) human Wilms tumour WiT49 cells into the left kidney. Arrows point at the tumour‐afflicted left kidney (A, B, C). Dashed arrows point at the unaffected right kidney (inset in B). Tumours appear as white areas with high signal intensity. Scale bar corresponds to 1 cm. Xenograft tumours were harvested and documented approximately 14 weeks after transplantation (D--F), followed by fixation of both kidneys in paraformaldehyde (PFA, G--I). Asterisks (\*) denote visceral fat of the left kidney (F, I). Black dashed arrows point at unaffected right kidneys. Visualisation of tumour histology was carried out by H&E stains of xenograft tumours (J--L). IHC p53 positivity demonstrates tumour areas (M--O), whereas WT1 nuclear positivity enhances epithelial tumour elements (P--R). Scale bar corresponds to 5 mm. NK, normal kidney. All immunostains are brown.](PATH-247-86-g003){#path5171-fig-0003}

![Loss of IRX3 promotes proliferative mesenchymal xenograft tumours, whereas loss of IRX5 stimulates differentiation of tumour tubules. (A) Tumour volumes based on MRI of NSG mice 12 weeks after xenograft transplantation with *wt*, *IRX3* and *IRX5* knockout orthotopic Wilms tumour xenografts. (B) The area of each tumour consisting of neoplastic tubules in *wt*, *IRX3* and *IRX5* knock out orthotopic xenografts. Boxplot represents median values and quartiles. (C--K): Detailed histological view of Wilms tumour orthotopic xenograft tumours with different IRX status, visualised by H&E staining (C, F, I) and IHC staining for p53 (D, G, J) and WT1 (E, H, K). The epithelial compartment of xenograft tumours was visualised by nuclear WT1 positivity, whereas p53 demarcated tumour cells from mouse host tissue. Within parentheses ( ) are the denotations of the specific xenograft tumours, listed in supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}. Scale bar corresponds to 400 μm. All immunostains are brown.](PATH-247-86-g004){#path5171-fig-0004}

Loss of IRX5 stimulates and maintains a differentiated state {#path5171-sec-0013}
------------------------------------------------------------

Tumours emerging from grafted *IRX5* ^−/−^ cells were either very small or were undetectable by MRI (see supplementary material, Table [S3](#path5171-supitem-0013){ref-type="supplementary-material"}). They were rarely visible macroscopically upon harvest (Figure [3](#path5171-fig-0003){ref-type="fig"}C,F,I) and their volumes were significantly smaller than *wt* and *IRX3* ^−/−^ tumours as measured by MRI (Figure [4](#path5171-fig-0004){ref-type="fig"}A; *p* = 0.002 and *p* = 0.009, respectively, Wilcoxon rank‐sum test) and microscopic analysis, respectively (Figure [3](#path5171-fig-0003){ref-type="fig"}L,O,R compared to Figure [3](#path5171-fig-0003){ref-type="fig"}J,K,M,N,P,Q). In fact, some *IRX5* ^−/−^ tumours were only possible to ascertain after p53 and WT1 IHC (see supplementary material, Figure [S6](#path5171-supitem-0008){ref-type="supplementary-material"}A--F). The size of the tumours indicated a low proliferation rate of *IRX5* ^−/−^ cells, which recapitulated the results shown *in vitro*. Notably, clone T5‐77 also formed small tumours despite its lack of suppressed proliferation *in vitro* (Figure [4](#path5171-fig-0004){ref-type="fig"}A and see supplementary material, Figure [S5](#path5171-supitem-0007){ref-type="supplementary-material"}). *IRX5* ^−/−^ tumours were histologically dominated by the epithelium (Figures [3](#path5171-fig-0003){ref-type="fig"}R and [4](#path5171-fig-0004){ref-type="fig"}K and see supplementary material, Figure [S6](#path5171-supitem-0008){ref-type="supplementary-material"}C,F), with significantly more tumour tubules compared to both *wt* and *IRX3* ^−/−^ tumours (*p* = 0.02 and *p* = 0.0004, Wilcoxon rank‐sum test; Figure [4](#path5171-fig-0004){ref-type="fig"}B--K). Their mesenchymal/stromal compartments were minimal or absent (see supplementary material, Figure [S6](#path5171-supitem-0008){ref-type="supplementary-material"}A--F). The two proteins did not appear to compensate for each other\'s expression in the xenograft knockout tumours, suggesting that other pathways downstream of the IRX proteins mediate the contrasting phenotypes (see supplementary material, Figure [S6](#path5171-supitem-0008){ref-type="supplementary-material"}G--J).

IRX3 and IRX5 knockout affects WNT and Hippo signalling in different ways {#path5171-sec-0014}
-------------------------------------------------------------------------

To unravel the signalling pathways involved in the distinct phenotypes of *IRX3* ^−/−^ and *IRX5* ^−/−^ tumours, targeted gene expression analyses of key genes for nephrogenesis was performed [27](#path5171-bib-0027){ref-type="ref"}. Here, *IRX5* ^−/−^ cells had a signature more similar to that of *wt* WiT49 cells than to *IRX3* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}A). This was consistent with the higher prevalence of nephrogenic tubules in *wt* and *IRX5* ^−/−^ tumours compared to that of *IRX3* ^−/−^ tumours. Both WNT and Hippo signalling are known to be involved in nephrogenesis through, for example, planar cell polarity (PCP), which is important for tubule formation [28](#path5171-bib-0028){ref-type="ref"}. Gene sets involved in both these pathways exhibited distinct expression signatures at comparison between *IRX3* ^−/−^ and *IRX5* ^−/−^ cells \[Figure [5](#path5171-fig-0005){ref-type="fig"}B,E; multi‐group comparison by analysis of variance (ANOVA)\]. WNT5A is a key player in kidney development. Besides acting via the non‐canonical PCP WNT pathway [29](#path5171-bib-0029){ref-type="ref"}, it can signal through the WNT receptor Fzd3 (reviewed in [30](#path5171-bib-0030){ref-type="ref"}, [31](#path5171-bib-0031){ref-type="ref"}, [32](#path5171-bib-0032){ref-type="ref"}). Downstream of WNT receptor Fzd3, the cell adhesion molecule Alcam acts via the non‐canonical WNT/JNK pathway to affect proximal tubule development [33](#path5171-bib-0033){ref-type="ref"}. Strikingly, *WNT5A*, *FZD3* and *ALCAM* were all upregulated in *IRX5* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}B,C). Expression data suggested that canonical β‐catenin WNT signalling was suppressed in *IRX5* ^−/−^ cells as genes involved in inhibition of β‐catenin (*CTNNBIP1*, *DKK3* and *KREMEN1*) were upregulated in *IRX5* ^−/−^ cells, and *CTNNB1* itself was downregulated (Figure [5](#path5171-fig-0005){ref-type="fig"}B). The reverse was true for *IRX3* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}B).

![WNT and Hippo signalling‐related genes are differently expressed between *IRX3*‐ and *IRX5*‐ko WiT49 cells. (A) Nephrogenesis‐related genes (23/54 genes, *p* = 0.02) and (B) WNT signalling‐related genes (19/84 genes, *p* = 0.01) were differently expressed between *wt*, *IRX3* ^*−/−*^ and *IRX5* ^*−/−*^ WiT49 cells at multi‐group comparison by ANOVA (false detection rate = 0.05). Extracted genes were subjected to hierarchical clustering, and results were graphically displayed as heat maps. For further details, see Materials and Methods and supplementary material, Supplementary materials and methods and Table [S7](#path5171-supitem-0017){ref-type="supplementary-material"}. Scatter plot displaying gene expression of the key nephron tubulogenesis gene *ALCAM* (C). GSEA supported the role of Hippo signalling in *IRX5* ^*−/−*^ WiT49 cells. (D; GSEA run against the C6 oncogenic signatures gene sets). In addition, Hippo‐related genes (21/76 genes, *p* = 0.01, multi‐group comparison by ANOVA) were differently expressed between *wt*, *IRX3* ^*−/−*^ and *IRX5* ^*−/−*^ WiT49 cells (E). The gene expression differences between *IRX3* ^*−/−*^ and *IRX5* ^*−/−*^ cells imply that Hippo and non‐canonical WNT signalling are promoted in *IRX5* ^*−/−*^ cells, whereas in *IRX3* ^*−/−*^ cells, canonical WNT signalling is activated, and Hippo signalling is inhibited (F). The heat map scale units apply to all heat maps (A, B and E).](PATH-247-86-g005){#path5171-fig-0005}

Hippo signalling is involved in the regulation of organ size, and it consists of a cascade of negative growth regulators. Hence, active Hippo signalling is considered important for nephrogenesis and the suppression of tumour formation [34](#path5171-bib-0034){ref-type="ref"}. The expression of genes involved in Hippo signalling was significantly enriched in *IRX5* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}D and see supplementary material, Table [S6](#path5171-supitem-0016){ref-type="supplementary-material"}D). In addition, specific genes important for the activation of Hippo signalling, such as *AMOT*, *AMOTL2*, *DCHS1*, *DCHS2* and the PCP‐related *FAT3* and *FAT4,* were upregulated in *IRX5* ^−/−^ cells compared to *IRX3* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}E). Taken together, our data suggested that canonical WNT signalling was promoted in *IRX3* ^−/−^ cells, whereas Hippo and non‐canonical WNT signalling were inhibited. The opposite was true for *IRX5* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}F).

WNT5A is a likely effector of nephrogenic tubule maturation {#path5171-sec-0015}
-----------------------------------------------------------

WNT5A is a key effector molecule in nephrogenesis and is also integrated with Hippo signalling [29](#path5171-bib-0029){ref-type="ref"}, [35](#path5171-bib-0035){ref-type="ref"}. It also plays a role in tumorigenesis and has been used to enforce the differentiation of colon cancer cells [36](#path5171-bib-0036){ref-type="ref"}. *WNT5A* mRNA expression was higher in *IRX5* ^−/−^ compared to *IRX3* ^−/−^ cells (Figure [5](#path5171-fig-0005){ref-type="fig"}B), while WNT5A protein was expressed in all histological elements of WiT49‐derived tumours irrespective of *IRX3/5* status (Figure [6](#path5171-fig-0006){ref-type="fig"}A--F). WNT5A‐positive mesenchymal cells were significantly more common in *wt* and *IRX5* ^−/−^ as opposed to the poorly differentiated *IRX3* ^−/−^ tumours (Fisher\'s exact test (two‐sided), *p* \< 0.01, supplementary material, Figure [S7](#path5171-supitem-0009){ref-type="supplementary-material"}), in line with its lower mRNA expression in the latter. WNT5A was primarily expressed in the maturing epithelial structures of the human foetal kidney (Figure 6G). In Wilms tumours, WNT5A showed the most prominent protein expression in tumour tubular epithelium, along with areas of surrounding stromal cells (Figure [6](#path5171-fig-0006){ref-type="fig"}H and supplementary material, Figure [S8](#path5171-supitem-0010){ref-type="supplementary-material"}A--F). Blastema was repeatedly negative (*n* = 6; Figure [6](#path5171-fig-0006){ref-type="fig"}H). Taken together, these data implicate a collaborative role of WNT5A and IRX3 in the promotion of tumour tubulogenesis.

![WNT5A is a likely differentiation‐promoting agent in Wilms tumour. WNT5A detected by IHC in WiT49‐based *IRX3* and *IRX5* knockout xenografts (A--F). Arrows point at WNT5A‐positive tumour tubules. Short arrows point at WNT5A‐negative stroma cells. Areas magnified ×3 of WNT5A‐negative stroma cells are inserted in (B) and (E). WNT5A expression in human foetal kidney at gestational week (gw) 10 and Wilms tumour (G and H, respectively). Arrowhead points at WNT5A‐positive stroma. Arrow with open arrowhead points at WNT5A‐positive metanephric mesenchyme. Arrows with filled arrowheads denote primitive nephrogenic elements. The insertion in H is a ×2 magnification of tumour tubules (H). Scale bars correspond to 100 μm. S = stroma. B = blastema. All immunostains are brown. (I) Cartoon depicting the proposed interplay between IRX3, IRX5 and WNT5A in nephrogenesis. IRX5 acts together with canonical/WNT‐β catenin signalling and disturbed Hippo signalling to maintain proliferative nephrogenesis. Polarisation and elongation are obtained via the integration of active Hippo and non‐canonical WNT signalling, where IRX3 and WNT5A, via stimulation of ALCAM, are crucial. Disturbed IRX3 and IRX5 expression, epitomised by Wilms tumour, inhibits MET and polarisation of immature mesenchyme. According to our model, exogenous WNT5A could potentially override the differentiation block present in Wilms tumour.](PATH-247-86-g006){#path5171-fig-0006}

Discussion {#path5171-sec-0016}
==========

Our study demonstrates that Irx3 and Irx5 are both expressed in primitive nephrons and regulate essential components of kidney formation in mice and humans. The expression pattern of IRX3 suggests its involvement primarily in the maturation of human nephrogenic structures, in line with the role of the Iroquois transcription factors in the patterning of nephrogenic tubules in the pronephros of zebrafish and amphibians [14](#path5171-bib-0014){ref-type="ref"}, [15](#path5171-bib-0015){ref-type="ref"}, [16](#path5171-bib-0016){ref-type="ref"}. In contrast, the IRX5 expression pattern indicated a role for it primarily in the maintenance of a proliferative pool of nephrogenic cells and the cells of early tubule formation. Apart from our study, the evidence for a role of Irx5 in nephrogenesis is sparse [12](#path5171-bib-0012){ref-type="ref"}. In accordance with the distinct roles of the two proteins in normal nephrogenesis, the *IRX3* ^−/−^ and *IRX5* ^−/−^ tumour cell phenotypes were in stark contrast to each other. *IRX3* ^−/−^ tumours had a shortfall of nephrogenic organisation with an extensive mesenchymal stromal element, whereas *IRX5* ^−/−^ tumours showed a differentiated nephrogenic pattern. Thus, our data strongly pointed to a differentiation‐promoting role for IRX3 in Wilms tumour and a role for IRX5 in maintaining a pool of cells with the proliferative features of the early metanephric mesenchyme in the WiT49 xenograft system. A similar role in primary Wilms tumour material would fit well with the fact that we detected IRX5 protein expression not only in tumour tubules but also in blastema and tumour stroma. However, the role of IRX3 in neoplasia is likely contextual as IRX3 rather blocks differentiation in acute leukaemia [37](#path5171-bib-0037){ref-type="ref"} and shows tumour‐promoting potential in hepatocellular carcinoma [38](#path5171-bib-0038){ref-type="ref"}.

An earlier study on a small sample set of Wilms tumours indicated that low mRNA expression of both *IRX3* and *IRX5* correlates to poor prognosis in Wilms tumour [6](#path5171-bib-0006){ref-type="ref"}. However, in the present study, loss of *IRX5* resulted in small, well‐differentiated tumours, which suggests an oncogenic‐like role for IRX5 in Wilms tumour, well in accordance with a recently proposed role as an oncogenic driver in prostate and colorectal cancer [39](#path5171-bib-0039){ref-type="ref"}, [40](#path5171-bib-0040){ref-type="ref"}, [41](#path5171-bib-0041){ref-type="ref"}. One plausible explanation for the seemingly contradictory role of IRX5 as a promotor of tumorigenesis on the one hand and the correlation of poor prognosis to its reduced mRNA expression on the other hand is its correlated expression with IRX3 in clinical material. In a situation where both genes are downregulated, it is feasible that the lack of differentiation caused by reduced IRX3 expression overrides the anti‐tumorigenic effects of reduced IRX5. What drives the expression of IRX5 in a Wilms tumour setting needs further investigation.

Our finding that IRX3 and IRX5 have central roles in nephrogenic differentiation highlights new possibilities to overcome the differentiation block that underlies Wilms tumour formation. The results presented here suggest that either the promotion of IRX3 signalling or inhibition of IRX5 signalling could be routes towards enforced differentiation in Wilms tumours. Disturbed Hippo signalling can cause nephron progenitors to differentiate into myofibroblasts [42](#path5171-bib-0042){ref-type="ref"}, and stromal--epithelial communication can act via Hippo signalling components, such as Fat4, Fat3 and Dchs1/2, to regulate kidney progenitor cell differentiation [43](#path5171-bib-0043){ref-type="ref"}, [44](#path5171-bib-0044){ref-type="ref"}, [45](#path5171-bib-0045){ref-type="ref"}. Thus, the bulky mesenchymal/stromal compartment of *IRX3* ^−/−^ xenograft tumours could be partly due to a low Hippo signalling activity compared to *IRX5* ^−/−^ tumours. A feasible way of targeting IRX3 or IRX5 is by indirect intervention with either WNT or Hippo signalling or both (reviewed in [28](#path5171-bib-0028){ref-type="ref"}, [46](#path5171-bib-0046){ref-type="ref"}).

WNT5A is involved in an alternative WNT pathway that is integrated with Hippo signalling [35](#path5171-bib-0035){ref-type="ref"}. At the same time, it is known that WNT5A acts to suppress tumour formation in several cancer types [36](#path5171-bib-0036){ref-type="ref"}, [47](#path5171-bib-0047){ref-type="ref"}, [48](#path5171-bib-0048){ref-type="ref"}. In colon cancer, it even induces differentiation of neoplastic cells [36](#path5171-bib-0036){ref-type="ref"}. A previous study showed that *WNT5A* is downregulated in Wilms tumour [49](#path5171-bib-0049){ref-type="ref"}. We specifically found lower WNT5A protein expression in stroma surrounding tumour tubules in *IRX3* ^−/−^ and wild‐type WiT49 cells compared to *IRX5* ^*−/−*^ cells, suggesting that it has a role in the induction of tubulogenesis in Wilms tumours. During organ development, Wnt5a is often secreted and directs PCP‐dependent cellular migration and patterning along concentration gradients [50](#path5171-bib-0050){ref-type="ref"}. In our material, IRX3 and WNT5A both exhibited the strongest IHC staining levels in maturing epithelial elements. This implies a concentration gradient based on diffusion from epithelial structures into the surrounding stroma and CM. Diffused WNT5A could then promote epithelial differentiation via, for instance, *ALCAM,* in turn leading to secondary endogenous WNT5A production through autocrine‐positive feedback [33](#path5171-bib-0033){ref-type="ref"}. An alternative explanation would be that WNT5A is negatively regulated by IRX5. However, this would be at odds with the coexistence of these two proteins in maturing renal tubules.

In summary, our data uniformly suggest a key role for IRX3 and IRX5 in mammalian nephrogenesis and Wilms tumour differentiation. We also find evidence for an important interplay between IRX3 and WNT5A in driving tubular maturation as summarised in Figure [6](#path5171-fig-0006){ref-type="fig"}I. This renders WNT5A a potential treatment agent for the enforced differentiation of Wilms tumours.
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